Knowledge and Attitudes of Oral Health Professionals to Different Dental Treatment Approaches in Bisphosphonate Therapy

Yıl 2025, Cilt: 35 Sayı: 2, 111 - 116, 20.04.2025

Yasemin Dedeoğlu İlknur Özenci , Cavid Ahmedbeyli Gökser Çakar Şebnem Dirikan İpci

https://doi.org/10.17567/currresdentsci.1677519

Öz

Objective: This study evaluates oral healthcare professionals’ attitudes towards managing different dental clinical scenarios considering different durations and administration routes of antiresorptive drugs.
Methods: This study is a cross-sectional, Web-based survey. The first part of the survey evaluated demographic data; the second part investigated dentists’ medication-related osteonecrosis of the jaw (MRONJ) treatment approach; the third part comprised clinical treatment scenario questions regarding the administration route and duration of usage. Oneway ANOVA test was used in the intergroup comparison of parameters showing normal distribution, and Tamhane's T2 test was used to determine the group that caused the difference. Student t-test was used for comparison of parameters showing normal distribution. The chi-square test, Continuity (yates) correction, and Fisher Freeman Halton test were used to evaluate qualitative data. Significance was set at P <.05.
Results: 35.8% of dentists said they would not treat at-risk patients as the correct approach. More than half of the participants prefer to refer to the cases of osteonecrosis from the 1st stage to a specialist. A statistically significant difference was found between the correct answers about all five treatment scenarios for patients receiving oral bisphosphonate (BP) 3 years in favor of experienced dentists (P <.05).
Conclusion: Within the confines of this study, dentists' knowledge of BP and osteonecrosis is moderate. Dentists with less than ten years of working experience are more cautious about patients using BP due to the risk of developing osteonecrosis when different dental treatments are performed.
Keywords: bisphosphonate, medication-related osteonecrosis of the jaw, awareness, survey

Anahtar Kelimeler

bisphosphonate, medication-related osteonecrosis of the jaw, awareness

Kaynakça

• 1. Ruggiero S, Dodson T, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-1956.
• 2. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117.
• 3. Verron E, Bouler JM. Is bisphosphate therapy compromised by the emergence of adverse bone disorders? Drug Discov Today. 2014;19(3):321-319.
• 4. Huja SS, Fernandez SA, Hill KJ, Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec- Part A Discov Mol Cell Evol Biol. 2006;288(12):1243–1249.
• 5. Vahtsevanos K, Kyrigidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356–5362.
• 6. Allen MR, Ruggiero SL. A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field. Int J Oral Maxillofac Implants. 2014;29(1):e45–e57.
• 7. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner Res. 2008;23(6):826–836.
• 8. Kim T,Kim S, Song M, et al. Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the jaw–like lesion in mice. Am J Pathol. 2018;188(10):2318–2327.
• 9. Kalra S, Jain V. Dental complications and management of patients on bisphosphonate therapy: A review article. J Oral Biol Craniofacial Res. 2013;3(1):25–30.
• 10. Kos M. Association of dental and periodontal status with bisphosphonate-related osteonecrosis of the jaws. A retrospective case controlled study. Arch Med Sci. 2014;10(1):117–123.
• 11. Kunchur R, Goss AN. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J. 2008;53(4):354–357.
• 12. Ripamonti CI, Maniezezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental
• preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137–145.
• 13. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117–120.
• 14. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341–1347.
• 15. Khamaisi M, Regev E, Yarom N, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab. 2007;92(3):1172–1175.
• 16. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008;66(4):625–631.
• 17. Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of Ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg. 2015;73(6):1095–1105.
• 18. López-Jornet P, Camacho-Alonso F, Molina-Miñano F, Gomez-Garcia F. Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: A preliminary study. J Eval Clin Pract. 2010;16(5):878–882.
• 19. Dahlgren M, Larsson Wexell C. Uncertainty managing patients treated with antiresorptive drugs: a cross-sectional study of attitudes and self-reported behavior among dentists in Sweden. Acta Odontologica Scandinavica. 2020;78(2):109-117.
• 20. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243-1251.
• 21. Albu-Stan IA, Petrovan C, Cerghizan D, Eremie LY, Crăciun AE, Copotoiu C. Knowledge and attitude of dentists regarding patients undergoing bisphosphonate treatment: a comparative questionnaire. J Interdiscip Med. 2018;3(3):169-172.
• 22. Gonzales CB, Young V, Ketchum NS, Bone J, Oates TW, Mungia R. How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network. Gen Dent. 2015;63(2):61–67.
• 23. Ahmadov R, Karacaoğlu F, Akkaya M. Knowledge, opinions and behaviors of dentists regarding bisphosphonates and bisphosphonate-related osteonecrosis of jaw. Türkiye Klinikleri J Dental Sci. 2018;24(2).
• 24. Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dent J. 2017;222(2):121–125.
• 25. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaw–2022 update. J Oral Maxillofac Surg. 2022;80(5):920-943.